Chromocell Therapeutics C... (CHRO)
Chromocell Therapeutics Corporation Statistics
Share Statistics
Chromocell Therapeutics Corporation has 6.03M shares outstanding. The number of shares has increased by 4.52% in one year.
| Shares Outstanding | 6.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -11.63% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.80M |
| Failed to Deliver (FTD) Shares | 418 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 58.23K, so 0.97% of the outstanding shares have been sold short.
| Short Interest | 58.23K |
| Short % of Shares Out | 0.97% |
| Short % of Float | 3.23% |
| Short Ratio (days to cover) | 0.26 |
Valuation Ratios
The PE ratio is -3.75 and the forward PE ratio is -0.58.
| PE Ratio | -3.75 |
| Forward PE | -0.58 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -4.3 |
| P/FCF Ratio | -28.22 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Chromocell Therapeutics Corporation.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01, with a Debt / Equity ratio of -0.2.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | -0.2 |
| Total Debt / Capitalization | -24.51 |
| Cash Flow / Debt | -0.77 |
| Interest Coverage | -13.23 |
Financial Efficiency
Return on equity (ROE) is 1.15% and return on capital (ROIC) is 132.58%.
| Return on Equity (ROE) | 1.15% |
| Return on Assets (ROA) | -76.57% |
| Return on Capital (ROIC) | 132.58% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.85M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Chromocell Therapeutics Corporation's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.8 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 91.47 |
| Average Volume (20 Days) | 895.38K |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.58M |
| Operating Income | -6.86M |
| Net Income | -7.38M |
| EBITDA | -6.86M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.28 |
Balance Sheet
The company has 96.39K in cash and 1.27M in debt, giving a net cash position of -1.17M.
| Cash & Cash Equivalents | 96.39K |
| Total Debt | 1.27M |
| Net Cash | -1.17M |
| Retained Earnings | -13.52M |
| Total Assets | 2.14M |
| Working Capital | -1.43M |
Cash Flow
In the last 12 months, operating cash flow was -981.03K and capital expenditures 1, giving a free cash flow of -981.03K.
| Operating Cash Flow | -981.03K |
| Capital Expenditures | 1 |
| Free Cash Flow | -981.03K |
| FCF Per Share | -0.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -45.88% |
| FCF Yield | -5.83% |
Analyst Forecast
Currently there are no analyst rating for CHRO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -35.48 |
| Piotroski F-Score | 2 |